National and International Policies on the Use of Biosimilars: An Environmental Scan
Peer-Reviewed Article in the Canadian Journal of Health Technologies
July 4, 2024
Biosimilars are biologic drugs that are highly similar to their reference biologics that were already authorized for sale. The objective of this Environmental Scan was to identify, synthesize, and understand national and international policies regarding biosimilar use.
Click to Read More.
The Canadian Biosimilars Forum
The Canadian Biosimilars Forum is an alliance of companies who represent the breadth of the biosimilars industry and who are collectively working to increase awareness, access and adoption of biosimilars across Canada. Learn more about the Forum
5 Key Facts About Biosimilars
Biosimilars are safe and effective medicines that treat diseases like cancer, diabetes, arthritis and inflammatory bowel disease.
Patients can expect no difference in efficacy and safety following a routine switch to a biosimilar.
A well-controlled switch policy protects patient choice.
Biosimilars could deliver over a Billion dollars in savings per year to the Canadian health care system.
Governments can use savings to provide more patients with access to more treatments.